Neutrophil-to-lymphocyte ratio (NLR) as a prognostic indicator of treatment response to novel hormones in metastatic castrate-resistant prostate cancer: Real-world data from a single institution.

被引：0
|
作者：
Scott, Emily [1 ]
Pasciuti, Katia [1 ]
Kubiak, Magdalena [1 ]
Marks, Gillian [1 ]
Needleman, Sarah [1 ]
Smith, Kate [1 ]
Prentice, Mark [1 ]
机构：
[1] Royal Free Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.52
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
52
引用
收藏
页数：2
相关论文
共 29 条
  • [21] Efficacy and safety profile of olaparib for patients with metastatic castration-resistant prostate cancer: A preliminary report of real-world data in a single institution in Japan
    Yasuda, Yosuke
    Sakurai, Masato
    Numao, Noboru
    Yamamoto, Shinya
    Yonese, Junji
    Yuasa, Takeshi
    INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (11) : 1060 - 1062
  • [22] Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data
    Flaig, Thomas W.
    Potluri, Ravi C.
    Ng, Yvette
    Todd, Mary B.
    Mehra, Maneesha
    CANCER MEDICINE, 2016, 5 (02): : 182 - 191
  • [23] Deployment of advanced real-world data (RWD) analytics for the accelerated recruitment of patients into an ongoing metastatic castrate-resistant prostate cancer (mCRPC) trial, together with the development of a sophisticated patient referral network
    Cushion, M. G.
    ANNALS OF ONCOLOGY, 2018, 29 : 301 - 301
  • [24] PROGNOSTIC VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER (MCRPC) PATIENTS RECEIVING A NEW AGENT (NA)-BASED THIRD-LINE TREATMENT. FINAL RESULTS FROM A MULTICENTER ITALIAN STUDY
    Caffo, Orazio
    Bria, Emilio
    De Giorgi, Ugo
    Tucci, Marcello
    Galli, Luca
    Fratino, Lucia
    Facchini, Gaetano
    Iacovelli, Roberto
    Lo Re, Giovanni
    Mosillo, Claudia
    Gasparro, Donatello
    Guglielmini, Pamela
    Damiani, Azzurra
    Procopio, Giuseppe
    De Lisi, Delia
    Ortega, Cinzia
    Scagliarini, Sarah
    Donini, Maddalena
    Sperduti, Isabella
    Basso, Umberto
    ANTICANCER RESEARCH, 2017, 37 (04) : 2156 - 2157
  • [25] Abiraterone prescribed by medical oncologist versus urologist in patients with metastatic castration-resistant prostate cancer: Real-world data from a public institution in Peru.
    Motta, Rodrigo
    Failoc, Virgilio
    Egoavil, Marina
    Gil, Fradis
    Roque, Katia Mercedes
    Llerena, Karina Mayra Aliaga
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] The prognostic value of the baseline neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving radium-223 (Ra-223): A post-hoc analysis of the ALSYMPCA phase-III trial
    Meisel, A.
    Parker, C.
    Kuhne, R.
    Sartor, O.
    Stenner-Liewen, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S524 - S525
  • [27] Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry
    Anders Bjartell
    Nicolaas Lumen
    Pablo Maroto
    Thomas Paiss
    Francisco Gomez-Veiga
    Alison Birtle
    Gero Kramer
    Ewa Kalinka
    Dominique Spaëth
    Susan Feyerabend
    Vsevolod Matveev
    Florence Lefresne
    Martin Lukac
    Robert Wapenaar
    Luis Costa
    Simon Chowdhury
    Targeted Oncology, 2021, 16 : 357 - 367
  • [28] Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry
    Bjartell, Anders
    Lumen, Nicolaas
    Maroto, Pablo
    Paiss, Thomas
    Gomez-Veiga, Francisco
    Birtle, Alison
    Kramer, Gero
    Kalinka, Ewa
    Spaeth, Dominique
    Feyerabend, Susan
    Matveev, Vsevolod
    Lefresne, Florence
    Lukac, Martin
    Wapenaar, Robert
    Costa, Luis
    Chowdhury, Simon
    TARGETED ONCOLOGY, 2021, 16 (03) : 357 - 367
  • [29] Comparative effectiveness of abiraterone and enzalutamide in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC): A retrospective cohort study in a large database of deeply curated EHR real-world data (RWD) from community oncology practices in the US.
    An, Huijun
    Schoen, Martin W.
    Rider, Jennifer
    Schorer, Anna E.
    Ken, Jessica
    Chen, Li
    Alabaster, Amy
    Natanzon, Yanina
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
123